Fig 1.
The switch of dosage and timing of tirofiban and aspirin throughout the trial.
In the tirofiban group, patients received tirofiban at a dosage of 0.04 μg per min per kg after randomization, which was later reduced to 0.01 μg after 30 mins and continued for 48 hours. Concurrently, patients in this group were given a placebo of 100 mg aspirin per day. Conversely, in the aspirin group, the drug and placebo were switched. Aspirin was administered at a dosage of 100 mg at the 44th hour after randomization, lasting for 90 days in both groups.
Fig 2.
Schematic of the short and long run model.
Patients in any mRS state could experience a recurrent stroke or non-stroke-related death. Those who experienced a recurrent stroke could die from it and would not be able to return to a lower mRS state. AIS: acute ischemic stroke. sICH: symptomatic intracranial hemorrhage. mRS: modified Rankin scale.
Table 1.
Key input parameters of the Markov model in the study.
Table 2.
The main results of costs and effectiveness in both China and the US.
Fig 3.
Tornado diagram depicting the impact of each parameter on the ICER.
Red represents the upper range of the parameter, while blue corresponds to the lower range of the parameter. Fig 3A displays the Tornado diagram of ICER in the China setting, while Fig 3B illustrates the Tornado diagram of ICER in the US setting. ICER denotes incremental cost-effectiveness ratio. In both China and the US, the mRS utility and the annual cost of post-hospitalization care had the most significant impact on the ICER. ICER: incremental cost-effectiveness ratio. mRS: modified Rankin scale. HR: hazards ratio. IV: intravenous. sICH: symptomatic intracranial hemorrhage.